Alzheimer's β-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner

Clinical and Experimental Immunology

Volumn 115, Issue 3, 1999, Pages 526-533

  Bergamaschini, Luigi ^a,b   Canziani, S ^a   Bottasso, B ^a   Cugno, M ^a   Braidotti, P ^a   Agostoni, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

amyloid peptide; C1q; Complement; Contact system

Indexed keywords

AMYLOID BETA PROTEIN; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4;

ALZHEIMER DISEASE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; HUMAN; INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN ASSEMBLY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COMPLEMENT C1Q; COMPLEMENT C1S; COMPLEMENT PATHWAY, CLASSICAL; FACTOR XII DEFICIENCY; FIBRINOLYSIS; HUMANS; MICROSCOPY, ELECTRON; PEPTIDE FRAGMENTS; PLASMIN;

EID: 0033041151     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00835.x     Document Type: Article

References (42)

1. Selkoe DJ. Alzheimer's disease: a central role of amyloid. J Neuropathol Exp Neurol 1994; 53:438-47.
2. Cotman CW, Tenner AJ, Cummings BJ. β-Amyloid converts an acute phase injury response to chronic injury response. Neurobiol Aging 1996; 17:723-31.
3. Lue LF, Rogers J. Full complement activation fails in diffuse plaques of Alzheimer's disease cerebellum. Dementia 1992; 3:308-13.
4. Pasinetti GM. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996; 17:707-16.
5. Itagaki S, Akiyama H, Saito H et al. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 1994; 645:78-84.
6. Veerhuis R, Janssen J, Hack CE et al. Early complement components in Alzheimer's disease brain. Acta Neuropathol 1996; 91:53-60.
7. Smith MD, Cribbs DH, Tenner AJ et al. Decreased levels of Clq in cerebrospinal fluid of living Alzheimer's patients correlate with disease state. Neurobiol Aging 1994; 15:609-14.
8. Rogers J, Cooper NR, Webster S et al. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1992; 89:10016-20.
9. Jiang H, Burdick D, Glabe CG et al. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the Clq A chain. J Immunol 1994; 152:5050-9.
10. Velazquez P, Cribbs DH, Poulos TL et al. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implication for Alzheimer's disease pathogenesis. Nature Med 1997; 3:77-79.
11. Webster S, Bradt B, Rogers J et al. Aggregation state-dependent activation of the classical complement pathway by the amyloid-β peptide. J Neurochem 1997; 69:388-98.
12. Snyder SW, Wang GT, Barret L et al. Complement Clq does not bind monomeric β-Amyloid. Exp Neurol 1994; 128:136-42.
13. Chen S, Frederickson RCA, Brunden KR. Neuroglial-mediated immunoinflammatory response in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol Aging 1996; 17:781-7.
14. Kaplan AP, Joseph K, Shibayama Y et al. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol 1997; 66:225-73.
15. Ratnoff OD, Naff GB. The conversion of C'ls to C'l esterase by plasmin and trypsin. J Exp Med 1967; 125:337-58.
16. Agostoni A, Gardinali M, Frangi D et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 1994; 90:2666-70.
17. Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer disease. Brain Res 1994; 654:234-40.
18. Bergamaschini L, Parnetti L, Pareyson D et al. Activation of the contact system in cerebro-spinal fluid of patients with Alzheimer's disease. Alzh Dis Assoc Dis 1998; 12:102-8.
19. Kingston IB, Castro MJM, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues. Nature Med 1995; 1:138-42.
20. Lammle B, Berrettini M, Griffin JH. Immunoblotting studies of coagulation Factor XII, plasma prekallikrein and high molecular weight kininogen. Sem Throm Hemost 1987; 13:106-14.
21. Berrettini M, Lammle B, White T et al. Detection of in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68:455-62.
22. Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chlorometyl ketone. Methods Enzymol 1981; 80:826-42.
23. Hoylaerts M, Rijken DC, Lijnen HR et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. J Biol Chem 1982; 257:2912-9.
24. Lennick M, Brew SA, Ingham KC. Kinetics of interaction of Cl inhibitor with Cls. Biochemestry 1986; 25:3890-8.
25. Ghebrehiwet B, Randazzo BP, Dunn JT et al. Mechanism of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71:1450-6.
26. Ghebreiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153:665-76.
27. Kuo Y-M, Emmerling ME, Vigo-Pelfrey C et al. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271:4077-81.
28. Snyder SW, Ladror US, Wade WS et al. Amyloid-β aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 1994; 67:1216-28.
29. Burdick D, Soreghan B, Kwon M et al. Assembly-and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992; 267:546-54.
30. Webster S, O'Barr S, Rogers J. Enhanced aggregation and β structure of amyloid β-peptide after coincubation with Clq. J Neurosci Res 1994; 39:448-56.
31. Nakajima K, Tsuzaki N, Takemoto N et al. Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. Brain Res 1992; 577:285-92.
32. Nakajima K, Tsuzaki N, Shimojo M et al. Production and secretion of plasminogen in cultured rat brain microglia. FEBS Letters 1992; 308:179-82.
33. Yamamoto M, Sawaya R, Mohanam S et al. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type I in human astrocytomas in vivo. Cancer Res 1994; 54:3329-32.
34. Walker DG, Yasuhara O, Patston PA et al. Complement Cl-inhibitor is produced by brain and is cleaved in Alzheimer's disease. Brain Res 1995; 675:75-82.
35. von Zabern I. Action of polyionic substances on the complement system. In: Sim B, ed. Activators and inhibitor's of complement. Dordrecht: Kluwer Academic Publishers, 1983:149-65.
36. Haydey RP, Patarroyo de Royas M, Gigli I. A newly described control mechanism of complement activation in patients with mixed cryoglobulinemia. J Invest Dermatol 1980; 74:328-32.
37. Ratnoff OD, Pensky J, Ogston D et al. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the Clr subcomponent of the first component of complement by serum Cl esterase inhibitor. J Exp Med 1969;129:315-71.
38. de Agostini A, Lijnen HR, Pixley RA et al. Inactivation of Factor XII active fragment in normal plasma. Predominant role of Cl-inhibitor. J Clin Invest 1984; 73:1542-9.
39. Ziccardi RJ, Cooper NR. Modulation of the antigenicity of Cls and Clr by Cl inactivator. J Immunol 1978; 121:2148-52.
40. Veerhuis R, Ianssen I, Hoozemans JJM et al. Complement Cl-inhibitor expression in Alzheimer's disease. Acta Neuropathol 1998; 96:287-96.
41. Roher AE, Chaney MO, Kuo Y-M et al. Morphology and toxicity of Aβ-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271:20631-5.
42. Thomas T, Thomas G, McLendon C. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-71.